http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020397822-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c207b493c33bab46d961c4b5b422ba7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2019-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18594bd6e0421f78b69a99d241a6f91a |
| publicationDate | 2020-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020397822-A1 |
| titleOfInvention | Personalized tumor antigen specific t cell lines for cancer treatment |
| abstract | The present invention relates to the immunotherapy of cancer. The present invention relates to develop personalized tumor antigen specific T cell lines to treat all types of cancer. The tumor antigen specific T cell lines provide potent and abundant tumor antigen specific T cells that selectively recognize cancer cells and destroy the cancer cells to cure cancer. Personalized tumor antigen specific T cell lines are a safe and effective immunotherapy for cancer treatment. It provides a promise that cancer will be no longer an incurable disease. |
| priorityDate | 2019-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.